New York, July 2, 2026, 17:03 EDT
- Johnson & Johnson NYSE:JNJ ended the session at $263.04, gaining 3.57%. Shares hit $263.10, which matches the 52-week high.
- J&J ended the day right over the average analyst target of $262.10 listed by WSJ, but still under the $265 median target.
- Dow gained 1.14%. S&P 500 ended little changed. Nasdaq Composite slipped 0.80%. NYSE and Nasdaq shut Friday for Independence Day.
Johnson & Johnson NYSE:JNJ climbed $9.06, or 3.57%, to finish at $263.04 Thursday. That’s about $21.8 billion added to its market cap based on 2.41 billion shares, according to WSJ. Shares also hit $263.10, matching the stock’s 52-week high. Volume came in at 7.9 million, just below the 65-day average.
For investors, the key isn’t the move in one session. The issue is the current price. J&J ended the day above the average analyst target of $262.10. That puts it just $1.96 below the $265 median target. The second-quarter results are coming, and there’s less room to absorb a miss.
| J&J measure | Latest figure | Investor read |
|---|---|---|
| Close | $263.04 | Above average target |
| Average target | $262.10 | Stock is above this level |
| Median target | $265.00 | 0.7% higher than the close |
| High target | $289.00 | 9.9% up from the close |
| Low target | $210.00 | Close is 20.2% over this mark |
The cross is important since earnings forecasts are mostly flat. WSJ’s table shows the second-quarter consensus at $2.85 per share, same as a month ago, down a bit from $2.89 three months ago. For 2026, the estimate sits at $11.58, barely changed from $11.56 three months back.
J&J jumped 3.57% for the day, well ahead of the index move. The Dow rose 1.14%, the S&P 500 finished flat, and Health Care/Life Sciences dropped 0.25%, WSJ data showed. The Nasdaq Composite slid 0.80%, according to MarketWatch.
| Market gauge | Thursday move | J&J spread |
|---|---|---|
| Johnson & Johnson | up 3.57% | — |
| Dow Jones Industrial Average | added 1.14% | beat by 2.43 pts |
| S&P 500 | flat | up 3.57 pts vs J&J |
| Nasdaq Composite | fell 0.80% | J&J led by 4.37 pts |
| Health Care/Life Sciences | slipped 0.25% | J&J ahead 3.82 pts |
J&J shares moved up before its second-quarter earnings call, set for July 15 at 8:30 a.m. ET, according to the company calendar.
J&J lifted its 2026 guidance in April, putting reported sales at $100.8 billion and adjusted EPS at $11.55 at the midpoint. CEO Joaquin Duato said the company had “a strong start to 2026.” Johnson & Johnson Investor Relations
April data hands bulls an argument, but also raises expectations. Johnson & Johnson’s first-quarter Innovative Medicine sales came in at $15.43 billion, up 11.2% reported. MedTech sales reached $8.64 billion, a rise of 7.7%.
| Segment | Q1 sales | Reported growth |
|---|---|---|
| Innovative Medicine | $15.43 bln | up 11.2% |
| MedTech | $8.64 bln | rose 7.7% |
| Worldwide | $24.06 bln | gained 9.9% |
Broad selling in tech shares weighed on the Nasdaq again, according to Reuters, with chipmakers slumping for another session. “You can really point the finger at the consolidation in the chips,” said Bruce Zaro, managing director at Granite Wealth Management. Adam Sarhan, CEO at 50 Park Investments, said the weaker jobs report “takes the pressure off the Fed to raise rates in the short term.” Reuters
Thursday is the last full trading day before the long weekend. NYSE and Nasdaq both say the market is closed on Friday, July 3, for the Independence Day holiday in 2026.
